Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain
IMPORTANCE OF THE FIELD: Despite proven analgesic efficacy, opioid use is associated with frequently dose-limiting bowel dysfunction that seriously impacts patients' quality of life (QoL). Agents used at present to manage opioid-induced constipation do not address the underlying opioid receptor...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2010
|
| In: |
Expert opinion on pharmacotherapy
Year: 2010, Jahrgang: 11, Heft: 2, Pages: 297-310 |
| ISSN: | 1744-7666 |
| DOI: | 10.1517/14656560903483222 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1517/14656560903483222
|
| Verfasserangaben: | Katri Elina Clemens, Gerd Mikus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1844699560 | ||
| 003 | DE-627 | ||
| 005 | 20230710135751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230505s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1517/14656560903483222 |2 doi | |
| 035 | |a (DE-627)1844699560 | ||
| 035 | |a (DE-599)KXP1844699560 | ||
| 035 | |a (OCoLC)1389805925 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Clemens, Katri Elina |d 1964- |e VerfasserIn |0 (DE-588)12260895X |0 (DE-627)082045836 |0 (DE-576)293346461 |4 aut | |
| 245 | 1 | 0 | |a Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction |b review of efficacy and safety data in the treatment of patients experiencing chronic pain |c Katri Elina Clemens, Gerd Mikus |
| 264 | 1 | |c 2010 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 23 December 2009 | ||
| 500 | |a Gesehen am 05.05.2023 | ||
| 520 | |a IMPORTANCE OF THE FIELD: Despite proven analgesic efficacy, opioid use is associated with frequently dose-limiting bowel dysfunction that seriously impacts patients' quality of life (QoL). Agents used at present to manage opioid-induced constipation do not address the underlying opioid receptor-mediated cause of bowel dysfunction and are often ineffective. There is, therefore, a significant need for more effective treatment options. The combination of the strong opioid oxycodone and the opioid antagonist naloxone has the potential to prevent opioid-induced bowel dysfunction (OIBD) while maintaining analgesic efficacy. - OBJECTIVE: To review the safety and efficacy of oral prolonged-release (PR) oxycodone/naloxone in the treatment of patients experiencing chronic pain. - AREAS COVERED IN THIS REVIEW: A MEDLINE search was done (January 2002 - July 2009) for available literature for prolonged release oxycodone and naloxone in different patient groups. Results were limited to English-language and clinical trials. Data were also obtained from congress materials. WHAT KNOWLEDGE THE READER WILL GAIN: Unmet needs of opioid pain treatment in terms of OIBD, reduced QoL and low treatment compliance, leading to reduced efficacy. A data overview demonstrates the efficacy and tolerability of PR oxycodone/naloxone in the management of severe chronic pain without the burden of severe gastrointestinal adverse events. The combined formulation of a highly effective opioid and an antagonist that acts locally to reduce gastrointestinal side effects is expected to simplify pain management. - TAKE HOME MESSAGE: The combination of PR oxycodone/naloxone offers the potential of maintaining normal bowel function in patients requiring opioid therapy--it is a strong analgesic that is well tolerated. | ||
| 650 | 4 | |a Administration, Oral | |
| 650 | 4 | |a Chronic Disease | |
| 650 | 4 | |a Clinical Trials as Topic | |
| 650 | 4 | |a Constipation | |
| 650 | 4 | |a Drug Administration Schedule | |
| 650 | 4 | |a Drug Therapy, Combination | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Naloxone | |
| 650 | 4 | |a Narcotic Antagonists | |
| 650 | 4 | |a Oxycodone | |
| 650 | 4 | |a Pain | |
| 650 | 4 | |a Pain Measurement | |
| 650 | 4 | |a Quality of Life | |
| 650 | 4 | |a Receptors, Opioid | |
| 650 | 4 | |a Safety | |
| 700 | 1 | |a Mikus, Gerd |e VerfasserIn |0 (DE-588)110903137 |0 (DE-627)691097941 |0 (DE-576)336988710 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on pharmacotherapy |d Abingdon, Oxon : Routledge, Taylor & Francis, 1999 |g 11(2010), 2 vom: Feb., Seite 297-310 |h Online-Ressource |w (DE-627)324741901 |w (DE-600)2030119-4 |w (DE-576)302969330 |x 1744-7666 |7 nnas |a Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction review of efficacy and safety data in the treatment of patients experiencing chronic pain |
| 773 | 1 | 8 | |g volume:11 |g year:2010 |g number:2 |g month:02 |g pages:297-310 |g extent:14 |a Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction review of efficacy and safety data in the treatment of patients experiencing chronic pain |
| 856 | 4 | 0 | |u https://doi.org/10.1517/14656560903483222 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230505 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 110903137 |a Mikus, Gerd |m 110903137:Mikus, Gerd |d 910000 |d 910100 |d 50000 |e 910000PM110903137 |e 910100PM110903137 |e 50000PM110903137 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 2 |y j | ||
| 999 | |a KXP-PPN1844699560 |e 4318257460 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"2010"}],"language":["eng"],"note":["Published online: 23 December 2009","Gesehen am 05.05.2023"],"physDesc":[{"extent":"14 S."}],"relHost":[{"recId":"324741901","id":{"issn":["1744-7666"],"eki":["324741901"],"zdb":["2030119-4"]},"origin":[{"dateIssuedDisp":"1999-","publisher":"Routledge, Taylor & Francis ; Informa Healthcare","publisherPlace":"Abingdon, Oxon ; London [u.a.]","dateIssuedKey":"1999"}],"pubHistory":["1.1999/2000 -"],"physDesc":[{"extent":"Online-Ressource"}],"part":{"pages":"297-310","year":"2010","issue":"2","extent":"14","text":"11(2010), 2 vom: Feb., Seite 297-310","volume":"11"},"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"EOP"}],"title":[{"title_sort":"Expert opinion on pharmacotherapy","title":"Expert opinion on pharmacotherapy","subtitle":"EOP"}],"disp":"Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction review of efficacy and safety data in the treatment of patients experiencing chronic painExpert opinion on pharmacotherapy","language":["eng"]}],"name":{"displayForm":["Katri Elina Clemens, Gerd Mikus"]},"id":{"doi":["10.1517/14656560903483222"],"eki":["1844699560"]},"recId":"1844699560","title":[{"title":"Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction","subtitle":"review of efficacy and safety data in the treatment of patients experiencing chronic pain","title_sort":"Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"roleDisplay":"VerfasserIn","given":"Katri Elina","display":"Clemens, Katri Elina","family":"Clemens","role":"aut"},{"role":"aut","family":"Mikus","roleDisplay":"VerfasserIn","given":"Gerd","display":"Mikus, Gerd"}]} | ||
| SRT | |a CLEMENSKATCOMBINEDOR2010 | ||